Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.81 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.81 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55299 | 0.90 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL2597485 | 0.88 | MTNR1A (0.84) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL30089783 | 0.88 | MTNR1A (0.84) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL2351965 | 0.88 | MTNR1A (0.84) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL9496504 | 0.86 | MTNR1A (0.67) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL7599844 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL7596840 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL55609 | 0.80 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL7599847 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 | |
| SCHEMBL6359193 | 0.79 | MTNR1A (0.79) | MTNR1AMTNR1BCYP1A2MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | MTNR1A 348/4885MTNR1B 225/4885CYP1A2 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.